MMSI

Business Context and Reporting Period

Company: Merit Medical Systems, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Merit designs, develops, manufactures, and markets single-use medical products for interventional and diagnostic procedures. The company operates primarily in four markets: cardiology, radiology, gastroenterology, and pulmonary. In 2009, the company significantly expanded its portfolio through the acquisition of assets from Alveolus (entering gastroenterology/pulmonary markets), Hatch (EN Snare retrieval system), and Biosearch (biliary stents).

Key Financial Metrics (Year Ended Dec 31, 2009)

Note: All figures are in thousands of dollars unless otherwise noted.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13% ($30.3 million) driven by a 12% increase in stand-alone devices, a 12% increase in custom kits, and a 23% increase in catheters. Acquisitions (Alveolus, Hatch, Biosearch) contributed $7.7 million in sales.
• Profitability: Net income rose 9% to $22.5 million. Gross margin improved by 120 basis points to 42.3% due to lower fixed overhead unit costs and reduced material costs.
• Expense Increases: Selling, general, and administrative (SG&A) expenses increased 22% ($11.7 million), primarily due to $5.7 million in expenses related to the Alveolus acquisition and hiring of additional sales staff. R&D expenses increased 22% to $11.2 million.
• Acquisitions: The company spent approximately $46.2 million on acquisitions in 2009, significantly impacting cash flow from investing activities and reducing working capital compared to 2008.
• Foreign Currency: Exchange rate fluctuations decreased gross revenues by approximately $2.6 million in 2009.

Guidance, Outlook, and Risks

Management Commentary: Management reported record sales and earnings for 2009. The company intends to continue exploring acquisition opportunities to enhance product offerings and improve gross margins. The effective income tax rate decreased to 32% in 2009 (from 35% in 2008) due to the profitability of Irish operations and R&D tax credits.

Risks and Contingencies:

• Healthcare Reform: Proposed legislation includes a fee or excise tax on medical devices which could adversely affect results if enacted.
• Concentration: Inflation devices accounted for approximately 24% of total revenues. The single largest customer (an OEM partner) accounted for approximately 6% of total sales.
• Intellectual Property: Risks related to patent infringement claims and the inability to protect proprietary technology.
• Supply Chain: Reliance on third-party suppliers for sterilization and manufacturing; disruption could materially affect operations.
• Regulatory: Subject to FDA and international regulations; failure to comply could result in product recalls or sanctions.

Key Facts for Investor Verification

• Acquisition Integration: Verify the successful integration and revenue contribution of the Alveolus, Hatch, and Biosearch assets, which drove significant expense increases and revenue growth.
• Cash Position: Cash and cash equivalents dropped significantly from $34.0 million in 2008 to $6.1 million in 2009 due to acquisition spending; verify the adequacy of remaining liquidity and the $30 million line of credit (with $7 million drawn).
• Product Concentration: Assess the risk associated with inflation devices representing nearly a quarter of total revenue.
• Foreign Operations: Monitor the impact of Euro and GBP exchange rate fluctuations, which accounted for 10% of sales and negatively impacted revenue by $2.6 million in 2009.
• Inventory Levels: Inventory increased from $38.4 million to $47.2 million; verify that obsolescence reserves are adequate given the expansion of product lines.